Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Original Makers Suspected of Obstructing Generic Houses' Business: JFTC
July 3, 2006
- SURVEY 3 articles
July 3, 2006
- Generic Makers Concerned about Extension of Data Protection Period: IGPA Conference
July 3, 2006
- Epadel, Atelec Continue to Drive Mochida's Business
July 3, 2006
- 66th Annual Scientific Sessions of the American Diabetes Association
July 3, 2006
- Blopress Retained Rank as Top-selling Drug in FY2005
July 3, 2006
- Pediatric Clinical Trial of Ketek Temporarily Discontinued in US: sanofi-aventis
July 3, 2006
- COMMENTARY 3 atricles
July 3, 2006
- Toyama Chemical Initiates PI Trial of Anti-RA Drug T-5224
July 3, 2006
- Average Wage Hike in Pharma Industry Higher Than All-Industry Average: Survey
July 3, 2006
- Bayer Initiates PIII for Antithrombosis Drug Rivaroxaban
July 3, 2006
- Bayer Succeeds in Taking Over Schering AG
July 3, 2006
- SEMINAR
July 3, 2006
- BUSINESS NEWS IN BRIEF
July 3, 2006
- R&D NEWS IN BRIEF
July 3, 2006
- SEMIANR
July 3, 2006
- Wyeth Celebrates 100 Years of Vaccine Leadership
July 3, 2006
- Combined Income-Outlay Reform Proposal Calls for Review of Range of Health Insurance Benefits
July 3, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 3, 2006
- Industry Prepared to Pay More Feesto Increase Number of Reviewers: Dr Aoki
July 3, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…